Klapstein Julie D 4

What Happened Julie D. Klapstein, a director of Omada Health, was granted 649 restricted stock units (RSUs) on July 5, 2026 under the company's Non‑Employee Director Compensation Program. The grant is reported at a $0.00 acquisition price (no cash exchanged); each RSU represents the right to receive one share of common stock upon settlement. This is an award/grant (transaction code A), not an open‑market purchase or sale, and is routine director compensation rather than a public market trade.

Key Details

• Transaction date: 2026-07-05; filing date: 2026-07-07 (timely Form 4 filing).
• Grant size and price: 649 RSUs granted at $0.00 (reported acquisition value $0).
• Shares owned after transaction: not specified in the filing.
• Footnote: RSUs were granted in lieu of retainer fees; each RSU equals one share and settlement will occur either on a date the director selects under the Program or as otherwise provided by the Program.
• Transaction type: Award/Grant (A). No indication of tax withholding, 10b5-1 plan, or late filing.

Context RSUs are a form of compensation that convert to company stock at settlement (subject to the compensation program's timing and any vesting). Because this grant was issued as compensation (not a purchase or sale), it shouldn't be interpreted as a direct bullish or bearish market signal by itself. The reported $0.00 simply reflects that no cash was paid to acquire these units at grant.